drugset / Trial / NCT02745535
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Phase 2
Completed
77 enrolled
University of Maryland, Baltimore
Gilead Sciences · collabUnity Health Care, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, and efficacy of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C infection who have failed to eradicate hepatitis C despite previous combination directly acting antiviral therapy.
Timeline
- Start
- 2016-05
- Primary completion
- 2018-10-24
- Completion
- 2018-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sofosbuvir | Small molecule | 400 mg | — |
| Subject | Voxilaprevir | Small molecule | 100 mg | — |
| Subject | velpatasvir | Other / unclassified | 100 mg | — |